Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Drug Design, Development and Therapy Volume 9, 2015 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Review

Spotlight on pembrolizumab in the treatment of advanced melanoma

Thanashan Rajakulendran1 Department of Medicine, Division of Dermatology, Postgraduate Medical Education, University of Toronto, Toronto, ON, CanadaCorrespondence[email protected]

David N Adam2 Department of Medicine, Division of Dermatology, St Michael’s Hospital, University of Toronto, Toronto, ON, CanadaCorrespondence[email protected]

Pages 2883-2886 | Published online: 04 Jun 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

ArisMBarrioMMCombining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatmentFront Immunol201564625709607
PubMed Web of Science ®Google Scholar
BhatiaSTykodiSSThompsonJATreatment of metastatic melanoma: an overviewOncology (Williston Park)200923648849619544689
PubMed Web of Science ®Google Scholar
KeeDMcArthurGTargeted therapies for cutaneous melanomaHematol Oncol Clin North Am201428349150524880943
PubMed Web of Science ®Google Scholar
RobertCKaraszewskaBSchachterJImproved overall survival in melanoma with combined dabrafenib and trametinibN Engl J Med20153721303925399551
PubMed Web of Science ®Google Scholar
MenziesAMLongGVSystemic treatment for BRAF-mutant melanoma: where do we go next?Lancet Oncol2014159e371e38125079100
PubMed Web of Science ®Google Scholar
RajakulendranTAdamDNBench to bedside: mechanistic principles of targeting the RAF kinase in melanomaInt J Dermatol201453121428143325311997
PubMed Web of Science ®Google Scholar
FedorenkoIVGibneyGTSondakVKSmalleyKSBeyond BRAF: where next for melanoma therapy?Br J Cancer2015112221722625180764
PubMed Web of Science ®Google Scholar
VinayDSRyanEPPawelecGImmune evasion in cancer: mechanistic basis and therapeutic strategiesSemin Cancer Biol Epub2015325
Web of Science ®Google Scholar
ShinDSRibasAThe evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next?Curr Opin Immunol201533C233525621841
PubMed Web of Science ®Google Scholar
CallahanMKWolchokJDAt the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapyJ Leukoc Biol2013941415323667165
PubMed Web of Science ®Google Scholar
RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
PubMed Web of Science ®Google Scholar
TumehPCHarviewCLYearleyJHPD-1 blockade induces responses by inhibiting adaptive immune resistanceNature2014515752856857125428505
PubMed Web of Science ®Google Scholar
PostowMACallahanMKWolchokJDImmune checkpoint blockade in cancer therapyJ Clin Oncol20151925332246
PubMedGoogle Scholar
MomtazPPostowMAImmunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathwayPharmgenomics Pers Med2014735736525484597
PubMedGoogle Scholar
RobertCSchachterJLongGVPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med Epub2015419
Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references